3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
32
Metastatic Castration-resistant Prostate Cancer
4
Kidney Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Carcinoma, Renal Cell
2
Urogenital Neoplasms
1
Thrombocytopenia
1
Renal Insufficiency
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Hormone Naive Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
1
Male Urogenital Diseases
1
Liver Neoplasms
1
High-Risk Localized Prostate Cancer
1
Glioma
1
Glioblastoma
1
Genital Neoplasms, Male
1
Disease
1
Cytopenia
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Astrocytoma
1
Anemia
1
Interventions
olaparib
1
gallium 68 PSMA-11
1
Pluvicto
1
Gemcitabine
1
Cisplatin
1
Androgen Antagonists
1
Adrenal Cortex Hormones
1
Abiraterone Acetate
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genital Neoplasms, Male
×
Pluvicto
×
1 year
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled